Exelixis Inc Other Receivables
Exelixis Inc (EXEL) had Other Receivables of $2.75 million as of 2012-12-31, per its 10-K filed 2013-02-21.
Discontinued › Notes › Nontrade Receivables
us-gaap:OtherReceivables · last filed 2013-02-21
- 2012-12-31: Other Receivables $2.75M.
- 2012-09-30: Other Receivables $2.71M.
- 2012-06-30: Other Receivables $2.28M.
- 2012-03-31: Other Receivables $1.93M.
| Period end | Other Receivables |
|---|---|
| 2012-12-31 | $2.75M 10-K · filed 2013-02-21 |
| 2012-09-30 | $2.71M 10-Q · filed 2012-11-07 |
| 2012-06-30 | $2.28M 10-Q · filed 2012-08-02 |
| 2012-03-31 | $1.93M 10-Q · filed 2012-05-03 |
| 2011-12-31 | $30.19M 10-K · filed 2013-02-21 |
| 2011-09-30 | $4.65M 10-Q · filed 2011-10-27 |
| 2011-06-30 | $6.36M 10-Q · filed 2011-08-04 |
| 2010-12-31 | $5.90M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |